Joseph M. Connors

90.7k total citations · 9 hit papers
423 papers, 35.8k citations indexed

About

Joseph M. Connors is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Joseph M. Connors has authored 423 papers receiving a total of 35.8k indexed citations (citations by other indexed papers that have themselves been cited), including 380 papers in Pathology and Forensic Medicine, 197 papers in Oncology and 115 papers in Genetics. Recurrent topics in Joseph M. Connors's work include Lymphoma Diagnosis and Treatment (377 papers), Viral-associated cancers and disorders (122 papers) and Chronic Lymphocytic Leukemia Research (111 papers). Joseph M. Connors is often cited by papers focused on Lymphoma Diagnosis and Treatment (377 papers), Viral-associated cancers and disorders (122 papers) and Chronic Lymphocytic Leukemia Research (111 papers). Joseph M. Connors collaborates with scholars based in Canada, United States and United Kingdom. Joseph M. Connors's co-authors include Randy D. Gascoyne, Marco A. Marra, Doug Horsman, Steven J.M. Jones, Jacqueline E. Schein, İnanç Birol, Martin Krzywinski, Kerry J. Savage, Laurie H. Sehn and Richard Klasa and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Joseph M. Connors

403 papers receiving 35.3k citations

Hit Papers

Circos: An information ae... 1999 2026 2008 2017 2009 2007 1999 2006 2012 2.5k 5.0k 7.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Circos: An information aesthetic for comparative genomics
    2009 7.8k citations Joseph M. Connors, Randy D. Gascoyne et al. profile →
  2. Revised Response Criteria for Malignant Lymphoma
    2007 3.2k citations Bruce D. Cheson, Randy D. Gascoyne et al. Journal of Clinical Oncology profile →
  3. Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas
    1999 2.8k citations Sandra J. Horning, Richard I. Fisher et al. Journal of Clinical Oncology profile →
  4. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP
    2006 1.0k citations Laurie H. Sehn, Brian Berry et al. Blood profile →
  5. Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
    2012 1.0k citations Anas Younes, Ajay K. Gopal et al. Journal of Clinical Oncology profile →
  6. Introduction of Combined CHOP Plus Rituximab Therapy Dramatically Improved Outcome of Diffuse Large B-Cell Lymphoma in British Columbia
    2005 744 citations Laurie H. Sehn, Jane Donaldson et al. Journal of Clinical Oncology profile →
  7. Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study
    2012 711 citations Ranjana H. Advani, Nancy L. Bartlett et al. Journal of Clinical Oncology profile →
  8. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era
    2013 609 citations Laurie H. Sehn, Leo I. Gordon et al. Blood profile →
  9. ALK− anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project
    2008 583 citations Kerry J. Savage, Joseph M. Connors et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Joseph M. Connors Canada 75 22.9k 14.7k 7.4k 7.2k 7.1k 423 35.8k
Randy D. Gascoyne Canada 99 26.1k 1.1× 17.4k 1.2× 9.7k 1.3× 11.5k 1.6× 6.4k 0.9× 493 43.9k
Elı́as Campo Spain 98 21.5k 0.9× 15.0k 1.0× 11.1k 1.5× 9.0k 1.3× 4.1k 0.6× 656 38.7k
Donna Neuberg United States 113 11.3k 0.5× 14.0k 1.0× 9.4k 1.3× 14.4k 2.0× 2.5k 0.4× 719 46.3k
Riccardo Dalla‐Favera United States 113 15.2k 0.7× 14.4k 1.0× 9.3k 1.3× 16.4k 2.3× 2.0k 0.3× 300 40.4k
Louis M. Staudt United States 97 10.8k 0.5× 9.4k 0.6× 6.3k 0.9× 15.4k 2.2× 1.7k 0.2× 293 34.8k
Kenneth W. Kinzler United States 163 25.2k 1.1× 49.2k 3.3× 6.9k 0.9× 79.7k 11.1× 2.8k 0.4× 381 131.7k
Peter Johnson United Kingdom 78 7.8k 0.3× 7.5k 0.5× 3.6k 0.5× 5.5k 0.8× 2.0k 0.3× 612 23.8k
Michael J. Keating United States 121 21.1k 0.9× 13.3k 0.9× 30.8k 4.1× 21.4k 3.0× 1.4k 0.2× 1.1k 66.6k
Robert A. Kyle United States 125 5.5k 0.2× 19.2k 1.3× 12.5k 1.7× 35.1k 4.9× 4.0k 0.6× 1.0k 59.9k
Carlo M. Croce United States 180 10.1k 0.4× 18.6k 1.3× 9.3k 1.2× 112.3k 15.7× 2.1k 0.3× 988 146.8k

Countries citing papers authored by Joseph M. Connors

Since Specialization
Citations

This map shows the geographic impact of Joseph M. Connors's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joseph M. Connors with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joseph M. Connors more than expected).

Fields of papers citing papers by Joseph M. Connors

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joseph M. Connors. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joseph M. Connors. The network helps show where Joseph M. Connors may publish in the future.

Co-authorship network of co-authors of Joseph M. Connors

This figure shows the co-authorship network connecting the top 25 collaborators of Joseph M. Connors. A scholar is included among the top collaborators of Joseph M. Connors based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joseph M. Connors. Joseph M. Connors is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ramchandren, Radhakrishnan, Ranjana H. Advani, Stephen M. Ansell, et al.. (2019). Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma. Clinical Cancer Research. 25(6). 1718–1726. 30 indexed citations
2.
Scott, David W., Rebecca L. King, Annette M. Staiger, et al.. (2018). High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology. Blood. 131(18). 2060–2064. 145 indexed citations
3.
Nielsen, Julie S., Aniqa Shahid, Zusheng Zong, et al.. (2015). Toward Personalized Lymphoma Immunotherapy: Identification of Common Driver Mutations Recognized by Patient CD8+ T Cells. Clinical Cancer Research. 22(9). 2226–2236. 18 indexed citations
4.
Boyle, Terry, Richard P. Gallagher, Randy D. Gascoyne, et al.. (2015). Lifetime Physical Activity and the Risk of Non-Hodgkin Lymphoma. Cancer Epidemiology Biomarkers & Prevention. 24(5). 873–877. 11 indexed citations
5.
6.
Mak, Vivien, Mukesh Chhanabhai, Tamara Shenkier, et al.. (2013). Survival of Patients With Peripheral T-Cell Lymphoma After First Relapse or Progression: Spectrum of Disease and Rare Long-Term Survivors. Journal of Clinical Oncology. 31(16). 1970–1976. 286 indexed citations
7.
8.
Younes, Anas, Ajay K. Gopal, Scott E. Smith, et al.. (2012). Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma. Journal of Clinical Oncology. 30(18). 2183–2189. 1014 indexed citations breakdown →
9.
Sehn, Laurie H., David W. Scott, Mukesh Chhanabhai, et al.. (2011). Impact of Concordant and Discordant Bone Marrow Involvement on Outcome in Diffuse Large B-Cell Lymphoma Treated With R-CHOP. Journal of Clinical Oncology. 29(11). 1452–1457. 146 indexed citations
10.
GWARTNEY, JAMES D. & Joseph M. Connors. (2009). The Crash of 2008: Causes and Lessons to Be Learned. Social Education. 73(2). 63–67. 1 indexed citations
11.
Savage, Kerry J., Nathalie A. Johnson, Susana Ben‐Neriah, et al.. (2009). MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood. 114(17). 3533–3537. 442 indexed citations
12.
Johnson, Nathalie A., Kerry J. Savage, Olga Ludkovski, et al.. (2009). Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood. 114(11). 2273–2279. 414 indexed citations
13.
Rimsza, Lisa M., Michael LeBlanc, Joseph M. Unger, et al.. (2008). Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP. Blood. 112(8). 3425–3433. 108 indexed citations
14.
Malumbres, Raquel, Jun Chen, Rob Tibshirani, et al.. (2008). Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. Blood. 111(12). 5509–5514. 73 indexed citations
15.
16.
17.
Farinha, Pedro, Hamid Masoudi, Brian Skinnider, et al.. (2005). Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood. 106(6). 2169–2174. 376 indexed citations
18.
19.
Connors, Joseph M.. (2002). Current clinical trials for advanced Hodgkin's lymphoma in North America: history, design and rationale. Annals of Oncology. 13. 92–95. 5 indexed citations
20.
Lee, Ann Y., Joseph M. Connors, Paul Klimo, Sean OʼReilly, & R. D. Gascoyne. (1997). Late relapse in patients with diffuse large-cell lymphoma treated with MACOP-B.. Journal of Clinical Oncology. 15(5). 1745–1753. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Randy D. Gascoyne Breakdown of academic impact, for papers by Elı́as Campo Breakdown of academic impact, for papers by Donna Neuberg Breakdown of academic impact, for papers by Riccardo Dalla‐Favera Breakdown of academic impact, for papers by Louis M. Staudt Breakdown of academic impact, for papers by Kenneth W. Kinzler Breakdown of academic impact, for papers by Peter Johnson Breakdown of academic impact, for papers by Michael J. Keating Breakdown of academic impact, for papers by Robert A. Kyle Breakdown of academic impact, for papers by Carlo M. Croce
Rankless by CCL
2026